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ABSTRACT 
The importance of pyrazole and lactam-based molecules in medical and pharmaceutical 
fields is underlined by the multitude of active ingredients on trade, such as Sildenafil or 
Apixaban, by Pfizer. In this work, a synthesis of an organic molecule with promising 
anticancer activity has been developed. This molecular scaffold is characterized by a δ-
lactam-fused pyrazolic core, with a well-known biological activity and amenable of 
further functionalization. The synthetic strategy adopted for the obtainment of the core 
was based on a 1,3-dipolar cycloaddition of a nitrilimine with an α,β-unsaturated δ-
lactam. Secondly, in order to give the final compound an elevated pharmacological 
activity, a functionalization with a double “side chain”, namely molecular fragment able 
to improve the interaction with particular biological receptors, was achieved. The target 
compound was thus obtained, with a highly convergent synthesis, and will be tested for 
antiproliferative activities towards different cellular lines. 
 
RIASSUNTO 
L’importanza di molecole contenenti eterocicli pirazolici e δ-lattami in ambito 
farmaceutico è evidenziata dalla grande quantità di principi attivi presenti sul mercato, 
quali il Sildenafil o l’Apixaban, commercializzate da Pfizer. Nel mio lavoro di tesi 
magistrale è stata sviluppata la sintesi di una molecola organica a potenziale attività 
farmacologica, caratterizzata da un pirazolo biciclico fuso con un δ- lattame, predisposto 
per successive funzionalizzazioni. La strategia sintetica adottata per l’ottenimento dello 
scheletro pirazolico si è basata su una cicloaddizione 1,3-dipolare di una nitril-immina 
con un δ-lattame α,β-insaturo. In secondo luogo si è proceduto, al fine di impartire al 
composto finale elevata attività farmacologica, ad un’ulteriore funzionalizzazione dello 
scheletro molecolare in precedenza ottenuto con una doppia “catena laterale”, ovvero un 
frammento molecolare in grado di interagire efficacemente con particolari recettori 
biologici. Si è infine ottenuto il prodotto “target”, che sarà sperimentato per attività 
antiproliferative nei confronti di svariate linee cellulari cancerose, in collaborazione con 
gruppi di ricerca nel campo medico-biologico. 
  
  
 
 
Table of contents 
1.  Introduction .............................................................................................................. 1 
1.1.  Lactams in medicinal chemistry ......................................................................... 1 
1.2.  Pyrazoles in medicinal chemistry ....................................................................... 3 
1.2.1.  Simple pyrazoles ......................................................................................... 3 
1.2.2.  Ring-fused pyrazoles .................................................................................. 6 
1.3.  “Side chains” in medicinal chemistry ................................................................. 9 
1.4.  Pyrazole synthesis ............................................................................................. 13 
1.4.1.  Cyclocondensation of 1,3-dielectrophilic compounds with hydrazines ... 13 
1.4.2.  1,3-Dipolar cycloadditions ....................................................................... 16 
1.4.3.  Synthesis of ring-fused pyrazoles ............................................................. 21 
2.  Aim of the Thesis .................................................................................................... 25 
3.  Results and Discussion. .......................................................................................... 29 
3.1.  Synthetic methodologies for the dipolarophile and precursor of the                
1,3-dipole………………….… ..................................................................................... 29 
3.1.1.  Synthetic strategies towards the α,β-unsaturated δ-lactam 
(dipolarophile)… ...................................................................................................... 29 
3.1.2.  Synthesis of the hydrazonoyl chloride, precursor of the 1,3-dipole……..32 
3.2.  1,3-Dipolar cycloaddition of the nitril-imine with the α,β-unsaturated δ-lactam 
followed by oxidation: synthesis of the ring-fused pyrazolic core ............................... 34 
3.3.  Synthesis of the “side chain” ............................................................................ 38 
3.4.  Functionalization and deprotection ................................................................... 40 
    3.5       Biological test………………………………………………………………... 44 
4.  Conclusions .............................................................................................................. 45 
5.  Experimental section .............................................................................................. 47 
6.  Bibliography ............................................................................................................ 61 
 
 
  
 
Introduction 
1 
 
1. Introduction 
1.1. Lactams in medicinal chemistry 
Lactams are cyclic amidic compounds, whose importance arises from the broad spectrum 
of applicability shown in modern industry. For example, ε-caprolactam and N-
vinylpyrrolidone find application in polymer industries as monomers for the synthesis of 
Nylon 6 and PVP (polyvinylpyrrolidone). N-methylpyrrolidone is used in petrochemical 
and plastics industries as a solvent, exploiting its non-volatility and capability to dissolve 
a wide range of materials (a less toxic alternative to typical high-boiling polar aprotic 
solvents such as HMPA, hexamethylphosphoramide or DMA, dimethylacetamide). 
Finally, β-lactams are well-known for their antibiotic properties, since the discovery of 
penicillin G by Fleming in 1928, and are present in a huge number of important drugs. 
 
Scheme 1. Some applications of lactams 
Nowadays, complex lactamic systems can be found predominantly in pharmaceutic and 
biologically active compounds, and take part in new libraries of molecules designed for 
drug discovery. For example, diastereoisomers I and II were found to be modulating 
agents for dopamine receptors (increasing antagonist compounds affinity) and are of 
potential interest for the treatment of neurologic and psychiatric disorders.1 
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Scheme 2. δ-Lactams as modulating agents for dopamine receptors 
One typical feature of lactams in medicinal chemistry is their better pharmacologic 
activity shown, compared to very similar non-cyclic amidic compounds. This fact 
underlines that the lactam itself plays a fundamental role in the interactions of the active 
core of the molecule with the biologic environment. In view of this, two literature 
examples may be reported. The first (Scheme 3a) shows two fibrinogen-receptors 
antagonists (III and IV), studied and used to prevent platelets aggregation in 
antithrombic therapy. Through computational studies and in vitro tests, it has been noted 
that, while compound III, bearing an aromatic-fused lactam, shows an IC50 of 25 mM, 
the corresponding non-cyclic amide IV is much worse performing, with a value of 530 
mM.2 Similarly, compound V, a naphthalene-fused δ-valerolactam, resulted much more 
effective against diabetes complicacies, than the corresponding naphtamide VI (Scheme 
3b).3 
 
Scheme 3. Lactams are often more active than non-cyclic amides 
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1.2. Pyrazoles in medicinal chemistry 
Pyrazole, a five membered aromatic heterocycle containing two adjacent nitrogen atoms, 
is a motif found in a number of small molecules that possess a wide range of 
pharmaceutical and agricultural4 activities.5 Moreover, some pyrazoles are used in the 
food industry, in supramolecular and polymer chemistry, as colorings or UV stabilizers,6 
in the chemistry of complexes with phosphorescent properties7 and as ligands for 
transition metal-catalyzed reactions.8 
 
Scheme 4. Some applications of pyrazole derivatives 
 
1.2.1. Simple pyrazoles 
More in detail, a large number of top selling drugs containing pyrazoles can be found, 
exhibiting antispasmodic, anti-inflammatory, antibacterial, antihyperglicemic, 
antidepressive and, more recently, antitumor activities.9 Even if it is true that quite 
recently the interest in pyrazole pharmaceutical activities has significantly increased, it is 
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also true that their biological properties are known since a very long time. The discovery 
of the antipyretic activity of pyrazole-family compounds is, in fact, attributed to Ludwig 
Knorr, who synthesized Phenazone (or Antipyrin), a simple pyrazolone, in 1883.  
 
Scheme 5. Phenazone and its synthesis by Ludwig Knorr 
In order to underline how many simple substituted pyrazoles are present on the market of 
pharmaceuticals, two much more recent examples may be reported. First of all, 
Celecoxib, a simple trisubstituted pyrazole, sold by Pfizer under the trade name of 
Celebrex, is used as a COX-2 (cyclooxygenase-2) selective nonsteroidal anti-
inflammatory drug (FANS), more or less equal to ibuprofen for postoperative pain and 
similar to paracetamol for pain relief. Moreover, experimental results showed its 
enhanced activity, compared to Indometacin (characterized by an indolic scaffold), 
against chronic pathologies, such as arthritis or ankylosing spondylitis.10 
 
Scheme 6. Celecoxib and Indometacin, two non-steroidal anti-inflammatory drugs 
Secondly, Crizotinib, sold by Pfizer under the trade name of Xalkori, is a disubstituted 
simple pyrazole with antitumor properties. It acts as inhibitor of a particular enzyme, 
codified by ROS-1 gene (proto-oncogene-1) and has obtained excellent results in clinical 
trials against anaplastic large cell lymphoma, neuroblastoma and other advanced state 
solid tumors.11 
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Scheme 7. Crizotinib, a simple pyrazole exhibiting anticancer activity 
In the last decades, discovery and development of new drugs for the treatment of the 
above-mentioned type of tumors (and many others) has been a challenging feature in 
medicinal chemistry and drug delivery research. For this purpose, pyrazolic systems are 
very often found as a recurrent molecular scaffold, synthesized in order to construct 
libraries of similar, same-core containing compounds. One of the most appealing 
characteristics of this type of anticancer molecules is the relatively low cost, compared to 
monoclonal antibodies (other large family of antitumor drugs), obtained through 
recombining DNA techniques.12 For example, recent molecular docking studies, 
followed by in vitro tests, have shown compounds VII and VIII as potential inhibitors of 
multikinase enzymes, responsible for the growth and the proliferation of HCC 
(Hepatocellular carcinoma) cells, a liver malignant tumor.13  
As another example, a new class of 3-carboxamido pyrazoles (IX), exhibiting various 
moieties attached via the amide linker, has been recently synthesized and tested both in 
vitro and in vivo as potent inhibitors of c-Jun N-terminal kinases, enzymes playing a key 
role in arthritis, metabolic diseases and cancer. These compounds have shown 
micromolar values of IC50 (half maximal inhibitory concentration) and significant anti-
inflammatory activity.in carrageenan induced rat paw edema.14 
 
Scheme 8. Carboxamido-pyrazoles showing anticancer properties 
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1.2.2. Ring-fused pyrazoles 
Ring-fused pyrazoles are, if possible, even more important than simple rings in the above 
mentioned applicative categories. An outstanding example is represented by Viagra 
(Sildenafil citrate), a very famous drug commercialized by Pfizer that reached a very 
high commercial success. Its central core is constituted by a pyrimidinone-fused 
pyrazole.  
 
Scheme 9. Sildenafil, active ingredient of Viagra 
A similar molecular motif is found in Allopurinol, a generic drug included in the World 
Health Organization’s List of Essential Medicine. It is used as an inhibitor of the 
xanthine-oxidase enzyme for the treatment of hyperuricemia, i.e. an excess of uric acid in 
blood. This molecule is very similar to xanthine (the substrate oxidized by the enzyme 
into uric acid) but differs for the five membered ring heterocycle. Thanks to the pyrazolic 
ring, instead of the imidazole of xanthine, Allopurinol is able to interact with the catalytic 
center of the enzyme, but is inert towards its oxidative cycle, behaving indeed as a 
catalyst poison.15  
 
Scheme 10. Allopurinol and Xanthine 
With the target molecule of this work in mind, citation of another ring-fused pyrazole is 
mandatory. Apixaban, developed by Bristol-Myers Squibb in collaboration with Pfizer, 
actually in phase III of clinical trials for the excellent anticoagulant properties, contains 
both the above-mentioned δ-lactamic and the present pyrazolic functionalities fused 
together. This drug is often prescribed in case of venous thromboembolism, acting as an 
inhibitor of the Xa factor, a serine protease that plays an important role in the coagulation 
cascade.16 Despite some side effects, compared to Warfarin (known under the trade name 
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of Coumadin), currently the most common drug for the treatment of this disease, 
Apixaban has been found to be “not inferior” in ictus prevention and superior in 
secondary hemorrhagings prevention.17 
 
Scheme 11. Apixaban and Warfarin, two anticoagulant drugs 
Moreover, condensed pyrazole derivatives have often shown antiproliferative activities 
towards a wide number of cellular lines and are often employed in anticancer drug 
discovery screening. For example, pyrazolo-[3,4-d]-pyrimidines (X) have been tested as 
potential Abelson Kinase inhibitors for the treatment of chronic myelogenous leukemia.18 
Furthermore, these molecules have shown promising antiproliferative properties towards 
breast and skin cancer cells.19 Similarly, some indazol-4-ones (XI) are at present in phase 
of clinic trials for the promising cytotoxicity shown, even at nanomolar concentrations. 
 
Scheme 12. Two ring-fused pyrazole derivatives exhibiting anticancer activity 
Finally, as another example, pyrrolo-[3,4-c]-pyrazole XII (Danusertib), an Aurora kinase 
inhibitor, has advanced in phase II clinical trials for the treatment of Bcr-Abl positive 
leukemias , due to the good pharmacokinetic properties as inhibitor of Aurora kinases 
and Bcr-Abl tyrosine kinase (mitosis regulators aberrantly overexpressed in cancer cells), 
along with  general safety profiles shown in phase I clinical studies. Compared with other 
hinge binder templates, its double heterocycle core offers efficient hydrogen bonds 
interactions, improving greatly its physiochemical properties.20 
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Scheme 13. Danusertib, a ring-fused pyrazole in clinical trials for the treatment of Bcr-Abl positive 
leukemias. 
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1.3. “Side chains” in medicinal chemistry 
Most often, molecules designed for medicinal chemistry (with either therapeutic or 
diagnostic purposes) are not constituted by a simple biologically active core, but are 
provided with one or more “side chains”. Typically these “side chains” are made of a 
“anchor agent”, connected through a “spacer” to the central molecular scaffold. The role 
of the “anchor agent” is to supply the molecule with a number of specific or generic 
interactions into the biological environment. On the other hand, the spacer serves as 
chemical linkage, but is also often designed in order to perform extra interactions and 
give the correct distance between the core and the ”anchor”, once they are placed in the 
desired biological site.  
More generally, one of the main aims of a “side chain” is to render the active core, which 
it is attached to, more specific for the desired biological target. Namely, thanks to the 
interactions of the ”anchor agent” with the biological environment near the selected site 
and the appropriate length of the spacer, the core is brought near to its binding position. 
The result is not only an enhanced affinity for the substrate but also an improved 
selectivity.  
For example, it has been demonstrated that cannabinoid molecules with different side 
chains (reported in Scheme 14) have different binding ability for their biological targets. 
Namely, cyclopropyl and cyclopentyl groups improve their affinity for CB1 and CB2 
cannabinoid receptors, compared to simple aliphatic chains (being therefore efficient 
pharmacophores), while cyclobutyl group renders them selective for CB1 and cyclohexyl 
groups quench the binding affinity for both of the receptors.21 
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Scheme 14. Molecules with the same core (red) and different side chains exhibit different binding 
affinities for their specific receptor. (Affinity is measured by mean of Ki, inhibition constant: namely, 
the concentration necessary to replace 50 % of a radiolabelled competitor ligand, already attached to 
the desired receptor). 
The other main goal prefixed in side chains design may be schematically called 
“differentiation” of the core. Modern drug discovery is indeed contingent on identifying 
lead compounds and rapidly synthesizing analogues.22 Therefore, in medicinal chemistry 
and drug design, once a promising central molecular scaffold has been found, it is 
common procedure to perform an ample screening of different “side chains”, in order to 
find the more active and selective compound. Moreover, upon variation of the side chain, 
it is possible to address the same active principle towards different biological receptors, 
expanding the applicability greatly. Finally, a different side chain not influencing the 
activity and the selectivity of the core may be desirable for pharmaceutical industries 
when the construction of analogues is concerned and violation of intellectual property 
may be involved.  
The elegant divergent synthetic approach reported in Scheme 15 has been thought in 
order to rapidly functionalize sulfonamide containing drugs, such as Celecoxib. The 
fascinating feature of the process is not only represented by the broad spectrum of 
feasible reactions and the atom-economy typical of a direct C-H bond activation, but 
arises also from the fact that the same pharmacophore (sulfonamide) acts as a 
regiochemistry director in all the functionalizations performed.22 
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Scheme 15. Divergent functionalization of Celecoxib 
In the previously reported examples some “anchor agents” have already been shown; 
however, additional mention should be given to terminal piperidine containing “side 
chains”, which can be found in a large class of pharmaceutical compounds (see 
Crizotinib, Sildenafil and Danusertib). With pH tunable hydrolytic properties (acidic 
when cationic, basic when neutral) these molecular fragments may influence greatly 
interactions with biological residues such as amino acids and cell membranes, conferring 
also water solubility at the organic molecule. 
For example, introduction of nitrogen containing, basic residues, covering ranges of 
pKa’s from 7 to 9.5, in the side chain (namely piperidines or N-methyl piperidines) 
originated in a great improvement for 4-anilinoquinazolines in the inhibition of KDR 
(kinase insert domain-containing receptor), active part of a key factor promoting cancer 
neovascularization and growth.23 
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Scheme 16. Effect of a N-methyl-piperidine on solubility and cytotoxicity 
Finally some structures of typical “spacers” should be underlined. Aliphatic chains, along 
with short polymer fragments are very common: the first for lipophilic interactions and 
great variability in the length and the latter for the ready availability and facile synthesis. 
However, other more elaborated “spacers” can be found; in particular, chains constituted 
by two or three p-diaminobenzene fragments are quite appealing for either hydrophilic 
(NH) and lipophilic (π-stacking) interactions, or the facility of the synthesis and the 
functionalization.  
 
Introduction 
13 
 
1.4. Pyrazole synthesis 
Conventional approaches for the preparation of substituted pyrazoles involve either the 
construction of two C-N bonds by cyclocondensation of hydrazines with 1,3-
dielectrophilic compounds (Scheme 17, via b) or the generation of one C-N and one C-C 
bond by 1,3-dipolar [3+2] cycloaddition (Scheme 17, via a). Each method has its own 
scope and efficiency limitations, however, general and efficient methodologies have been 
developed, following these general strategies, with the aim of increasing the yield and the 
regioselectivity in the preparation of substituted pyrazoles.5 
 
Scheme 17. General approaches for the synthesis of pyrazole 
 
1.4.1. Cyclocondensation of 1,3-dielectrophilic compounds with 
hydrazines 
The most common synthetic method for the preparation of functionalized pyrazoles 
involves the cyclocondensation (often called Knorr or Knorr-type reaction) of the 
appropriate hydrazine (mainly arylhydrazines), which acts as a double nucleophile, with 
a three-carbon unit featuring two electrophilic carbons in a 1,3 relationship, such as 1,3-
dicarbonyl or α,β-unsaturated carbonyl compounds. 1,3-Diketones, β-ketoesters and 2,4-
diketoesters can be efficiently condensed with hydrazines, affording simple pyrazoles 
bearing various alkyl or aryl substituents. However, starting from unsymmetrical 1,3-
dicarbonyl compounds, mixtures of two regioisomers are often obtained in reactions with 
substituted hydrazines. On the other hand, condensation of hydrazines with α-enones 
regioselectively leads to pyrazolines, which must then be oxidized to the corresponding 
pyrazoles.5 
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Scheme 18. General cyclocondensation reaction of hydrazines with 1,3-dicarbonyl compounds 
 
 
Scheme 19. Cyclocondensation of phenylhydrazine with α,β-unsaturated compounds followed by 
oxidation24. 
The regioselectivity of these cyclocondensations has been widely investigated and has 
been found to be dependent on a delicate equilibrium between the different reactivity of 
the groups involved in the condensation, and steric-electronic effects of the substituents 
on the hydrazine and the 1,3-dielectrophile, with solvent, concentration and temperature 
effects playing also an important role, both under thermodynamic and kinetic control 
reaction conditions.5 For example, in the cyclocondensation of β-aryl, aryl-ynones with 
hydrazines reported in Scheme 20, the observed regioselectivity was explained as a 
result of an initial 1,4-coniugate addition of the more nucleophilic nitrogen (methyl-
substituted in methylhydrazines and unsubstituted in arylhydrazines) to the triple bond of 
the ynone system.25  
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Scheme 20. Example of regiochemistry control in cyclocondensation reactions 
The versatility of this synthetic pathway is underlined not only by the huge number of 
examples of “classic” reactions that can be found in the past and recent literature, but 
also by its application in new synthetic methods, such as solventless or solid-phase 
synthesis. However, these last strategies, despite the high yields, short reaction times and 
operationally convenient conditions, often lack of selectivity.5 
Finally, with the target molecule of this work in mind, particular attention must be paid 
to synthetic strategies aiming for ring-fused pyrazoles and pyrazole-3-carboxylates. 
While a variety of examples for either the first (Scheme 21)26 or the latter (Scheme 22,27 
Scheme 18 via c) is reported in recent literature, to our knowledge, no cyclocondensation 
method is known to produce, at the same time, a ring-fused pyrazole-3-carboxylate. 
 
Scheme 21. Cyclocondensation leading to a ring-fused pyrazole 
 
 
Scheme 22. Cyclocondensation leading to a pyrazole-3-carboxylate 
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1.4.2. 1,3-Dipolar cycloadditions 
The 1,3-dipolar cycloaddition reaction has been employed as one of the most powerful 
synthetic tools to provide substituted pyrazoles. Three main classes of 1,3-dipoles have 
been used as [C,N,N] synthons, namely, diazoalkanes, azomethine imines and 
nitrilimines; the [C,C] fragment usually comes from activated π-bonds of alkanes and 
alkynes. Compared to cyclocondensations between hydrazines and 1,3-dielectrophiles, 
1,3-dipolar cycloadditions are intrinsically more highly regioselective owing to the 
significant electronegative difference between the N and the C atom of the substrate.5 
 
Scheme 23. Most common dipoles for 1,3-dipolar cycloadditions leading to pyrazoles 
1,3-Dipolar cycloadditions of diazo compounds with alkynes, leading to N-unsubstituted 
pyrazoles, can be conducted efficiently under thermal conditions. However, diazo 
compounds are dangerous to prepare and handle due to their toxicity and potentially 
explosive nature.5 Nevertheless, either methods starting from commercially available, 
quite stable substrates (such as the Ohira-Bestmann reagent28 shown in Scheme 24) or 
generating the unstable diazo compound in situ29 (Scheme 25) are reported, also in recent 
literature. 
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Scheme 24. Cycloaddition of nitroalkenes with Ohira-Bestmann reagent (aromatization occurs by 
spontaneous HNO2 elimination)  
 
 
Scheme 25. In situ formation of the diazo compounds from tosyl-hydrazones and cycloaddition 
Azomethine imines are reactive intermediates generated in situ by various methods, 
generally starting from hydrazones, by thermal decomposition or acid treatment. As a 
more regioselective direct alternative to the Knorr reaction, the 1,3-dipolar cycloaddition 
of azomethine-imines with activated π-bonds turned out to be an appealing method for 
the library synthesis of pharmaceutically relevant pyrazoles for drug discovery efforts. 
This is shown in Scheme 26, following a literature example.30 
 
Scheme 26. Azomethine imine formation and cycloaddition 
Nitrilimines are generated in situ by treatment of hydrazonoyl halides with a base. Their 
1,3-dipolar cycloaddition to alkynes (Scheme 27, via a31) or alkenes bearing a leaving 
group (such as α-bromo-α,β-unsaturated aldehydes in Scheme 27, via c32) leads directly 
to pyrazoles, while addition to simple activated double bonds produces pyrazolines 
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(Scheme 27, via b31) that must be subsequently oxidized to the desired aromatic 
pyrazole. (Examples in Scheme 27 are from very recent literature). 
 
 
Scheme 27. Nitrilimine formation and cycloaddition with alkynes (a), alkenes followed by oxidation 
(b) and alkene bearing a leaving group (c) 
A very convenient prerogative of this synthetic strategy relies on the facile control and 
modification of the regiochemistry, as proved in our laboratories. For example, a 
catalytic amount of scandium triflate, Sc(OTf)3, as Lewis acid, is responsible for the 
inversion of the regioisomeric ratio in the cycloaddition of N-aryl-C-carboxyalkyl 
nitrilimine and an activated acetylene, such as N-phenyl-propiolamide.33  
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Scheme 28. Regioselectivity reversion with Sc(OTf)3  
Moreover, the electronic nature of the activating substituent of the multiple bond acts as 
a director of regiochemistry. In particular, electron donating groups (EDG), such as 
sulfide in Scheme 29, lead to 5-substitued pyrazoles, while electron-withdrawing groups 
(EWG) such as sulfone in Scheme 29, lead to 4-substitued pyrazoles as major products. 
These experimental results were broadly investigated by our research group and were 
confirmed by computational calculations as an interaction between distorted frontier 
molecular orbitals (HOMO-LUMO) both on the dipolarophile and on the nitrilimine 
dipole.34 
 
Scheme 29. Regioselectivity directed by acetylene substituents 
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The 1,3-dipolar cycloaddition of nitrilimines with activated π-bonds has proved to be a 
very powerful tool in the regioselective synthesis of biologically active pyrazole-based 
molecules, such as Rimonabant, Apixaban (see Scheme 11) and many others. The 
synthesis of Celecoxib shown in Scheme 30 may be taken as an example. 
Cyclocondensation reactions lead to mixtures of regioisomers, requiring the development 
of a crystallization protocol to obtain a regiopure material, or needed intermediates of 
complicated synthesis, whose purifications relied on column chromatography. On the 
other hand, the 1,3-dipolar cycloaddition strategy furnished the desired pyrazole in 52% 
overall yield from starting material (4-sulfonamide-phenylhydrazine hydrochloride) with 
a simple, practical and 100% regioselective protocol, employing economical and readily 
available reagents.35 
 
Scheme 30. Celecoxib synthesis through 1,3-dipolar cycloaddition strategy (in the last step, 
aromatization occurs by morpholine elimination) 
Finally, to underline the versatility and the generality of this strategy, a very recent 
literature example, employing it successfully on an unusual substrate, is to be cited. Lu et 
al. reported a stable pyrazole-ring fused derivative of a endohedral metallofullerene, 
synthesized by regioselective 1,3-dipolar cycloaddition of diphenylnitrilimine to Sc3N@ 
C80. (Scandium nitride encapsulated in a C80 fullerene).
36 
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Scheme 31. 1,3-dipolar cycloaddition of diphenylnitrilimine using a fullerene as dipolarophile 
 
1.4.3. Synthesis of ring-fused pyrazoles 
Because of the excellent bioactivity and the wide range of application, thousands of 
papers concerning the synthesis of condensed pyrazole derivatives have been published4. 
However, it is possible to summarize all these strategies into three main classes: methods 
starting from a pre-formed ring to which the pyrazole is subsequently fused, methods 
starting from a pre-formed pyrazole to which a new ring is subsequently fused and, 
finally, methods generating both pyrazole and its fused ring at once, following one-pot 
reaction procedures. In Scheme 32 the three above-mentioned strategies are exemplified, 
showing the synthesis of the same pyrazole-pyridinic core in different target 
molecules.37,38,39 
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Scheme 32. Three different strategies to create the same bicyclic pyrazole core 
Multicomponent one-pot syntheses are well known to produce highly functionalized, 
complex molecular scaffolds in very convenient, step- and atom-economical procedures. 
Nevertheless, the outcome of these reactions is very often difficult to predict and control, 
rendering this strategy quite unappealing for the synthesis of a precise target compound. 
On the other hand, methods condensing a new cycle on the pyrazole ring suffer from the 
complexity of the direct functionalization of an heterocycle of hybrid electronic 
characteristics, not yet completely investigated and understood.4 
Hence, strategies constructing the pyrazole on pre-existing rings seem to be the more 
convenient pathway to condensed pyrazole derivatives, due to the wide spectrum of 
synthetic methods for the obtainment of the heterocycle, also from very different starting 
materials.5 For these reasons, our research group has quite recently reported a new 
synthetic procedure leading to cycloalkenone, lactone, thiolactone and lactam-fused 
pyrazoles, employing the 1,3-dipolar cycloaddition of various nitrilimines with α,β-
unsaturated cyclic systems.40  
 
Scheme 33. Cycloaddition of nitrilimines with various α,β-unsaturated cyclic systems 
Finally, the regiochemistry of the reaction was broadly investigated and the experimental 
results were justified through theoretical and computational studies. In most cases, 5-
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acyl-pyrazole derivatives were found to be the major products; although, only small and 
hard dipolarophiles (cyclopentanone and α,β-unsaturated γ-butyrolactone) reacted with 
electron-rich nitrilimines (such as N-p-methoxyphenyl, C-carboxymethyl nitrilimine) 
under the mandatory presence of Et3N as a base, giving an inversion in the selectivity, in 
favour of 4-acyl-pyrazoles.40  
 
Scheme 34. Major product arising from cycloaddition-oxidation of N-p-methoxyphenyl, C-
carboxymethyl- nitrilimine and each of the shown dipolarophiles 
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2. Aim of the Thesis 
In the previous chapter the importance of pyrazoles and lactams derivatives in medicinal 
chemistry has been underlined, along with a brief discussion about “side chains” in drug 
design. 
Aim of this thesis is the synthesis of a complex molecular target with potential 
pharmacologic activity, formed by a lactam-fused pyrazolic central scaffold and a double 
“side chain”. Retrosynthetic analysis, starting from the final product, may help in 
recognizing the different parts and foreseeing the synthetic strategy adopted. 
 
Scheme 35. Retrosynthetic analysis from building blocks to the final target 
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Following the disconnection approach, it is clear that three building blocks are necessary 
for the synthesis of the desired product: the α,β-unsaturated δ-lactam, the hydrazonoyl 
chloride and the “side chain”.  
Since none of the three building blocks is commercially available, their synthesis will be 
the first effort towards the construction of the main intermediates. While the hydrazonoyl 
chloride can be synthesized with a common literature procedure, the obtainment of the 
α,β-unsaturated δ-lactam will not prove trivial and many strategies will be envisioned 
and attempted. Finally, the side chain will be synthesized through a series of aromatic 
functionalizations and reductions, improving a method already established by our group. 
 
Scheme 36. Retrosynthetic analysis for the hydrazonoyl chloride 
 
 
Scheme 37. Retrosynthetic analysis for the α,β-unsaturated δ-lactam (three possible ways) 
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Scheme 38. Retrosynthetic analysis for the “side chain” 
As one can see in Scheme 35, construction of the central core will be achieved by 1,3-
dipolar cycloaddition, followed by oxidation, between the α,β-unsaturated δ-lactam 
(dipolarophile) and the nitrilimine (dipole) derived from the hydrazonoyl chloride (see 
chapter 1.4.2 and 1.4.3). This straightforward and regioselective synthetic strategy, for 
ring-fused pyrazoles, has been firstly reported by our research group (see Scheme 34). 
Optimization of reaction conditions and selectivity will be broadly investigated.  
Attachment of the “side chain” will be subsequently attempted via amide bond formation 
between the two acid moieties on the central core and terminal reactive amine on the 
“spacer” of the side chain. This is a very common procedure in medicinal chemistry, due 
to both the high stability of the amide bond and the multitude of mild and functional 
groups-tolerant synthetic methods for its formation.  
As the last step, removal of the protecting groups will afford the final target. In view of 
this, introduction of suitable protecting groups with the same cleavage method, in the 
early steps of the synthesis, will be a smart choice to afford, at the end of the process, a 
step-economical, one-pot multiple deprotection. 
At the end of this highly convergent synthesis a double functionalized bicyclic lactam-
fused pyrazole system will be obtained, ready to be tested for its cytotoxicity towards 
various cancerous cell lines. 
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3. Results and Discussion. 
3.1. Synthetic methodologies for the dipolarophile and precursor of 
the 1,3-dipole 
Our first efforts in the synthesis of the desired molecular target, were to find practical and 
scalable synthetic routes to an α,β-unsaturated δ-valerolactam and a hydrazonoyl chloride 
(precursor of the 1,3-dipole nitril-imine), suitable for the [3+2] dipolar cycloaddition 
reaction, in order to obtain the central ring-fused pyrazolic scaffold.  
 
3.1.1. Synthetic strategies towards the α,β-unsaturated δ-lactam 
(dipolarophile) 
A well-known literature procedure (developed by C. Marson and U. Gabrowska) 
involves an acid catalyzed condensation of a 3-alkenamide on an aryl-aldehyde followed 
by a mixed Bischer-Napieralski and Pictet-Spengler-type cyclization, leading to highly 
functionalized α,β-unsaturated δ-valerolactams with good stereo- and regiochemistry.41 
Despite its simplicity, this method is unsuitable for our purpose, aiming for an 
unsubstituted cycle.  
 
Scheme 39. Marson and Gabrowska method 
Another very established strategy is the ring closing metathesis, promoted by the 
Ruthenium-based “Grubbs catalysts”.42 The synthetic sequence leading to the 
unprotected lactam 1a was reported in literature43 and was attempted by our research 
group. However, besides the high cost of the substrates (homoallylamine in particular), 
this method proved also to be quite unpractical and very difficult to scale up on a 
laboratory scale, requiring very high dilution and a slight high amount of the very 
expensive Grubbs II generation catalyst. While the less expensive I generation one was 
attempted and promoted successfully the reaction, it required an even higher amount of 
catalyst, which proved to be inseparable from the product. This one, in the crude form, 
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failed to undergo the subsequent protection reaction, probably due to traces of impurities 
and the strategy had to be discarded. 
 
Scheme 40.Ring-closing metathesis method 
With the most common ring-closing methods set apart, we moved our attention on 
strategies aiming for α,β-unsaturated cyclic products, starting from the corresponding 
saturated ones (in this case being the inexpensive and commercially available δ-
valerolactam). One common procedure is the Saegusa-Ito oxidation, a Pd(II) promoted β-
hydrogen extraction performed on silyl-enol ethers.44 While it represents a very 
established procedure for cyclic ketonic substrates, we failed to find any examples in 
literature about its application on esters or amides. The reaction was attempted anyway 
but led only to trace-amounts of the desired product. 
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Scheme 41. Saegusa-Ito oxidation strategy 
Finally the “selenoxide elimination” method45 was taken into account as a suitable 
synthetic strategy. This route proved to be the most efficient and easy to perform on a 
multigram laboratory scale, with the stoichiometric requirement of the toxic (but quite 
inexpensive) organoselenium compound (phenylselenyl bromide, PhSeBr) being the only 
drawback. However, the reagent itself is quite safe to handle and its toxicity should not 
be of any concern for the final pharmaceutical target, having been used and removed in a 
very early synthetic step.  
For these reasons a three-step procedure was developed and optimized. The process 
started with the protection of the amide functionality as methoxy-methyl hemiaminal by 
treatment of δ-valerolactam with n-butyllithium and chloromethyl methyl ether (MOM-
Cl) in anhydrous THF. Product 1 was thus obtained in 77% yield after purification either 
by column chromatography on silica gel or by distillation under reduced pressure. 
 
Scheme 42. Selenoxide elimination method, 1st step 
In the second step, α-selenylation of the carbonyl was achieved by reacting product 1 
with LDA (lithium diisopropylamide) and PhSeBr in anhydrous THF. Product 2 was thus 
obtained in 65% yield after purification by column chromatography on silica gel.  
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Scheme 43. Selenoxide elimination method, 2nd step 
In the last step the selenoxide was formed by treatment of compound 2 with concentrated 
H2O2 in THF at 0 °C (where it is stable) and thermally decomposed (eliminated) by 
rising the reaction temperature above 22 °C in a (highly exothermic) one-pot oxidation-
reverse cycloaddition reaction. After purification by column chromatography on silica 
gel, which easily afforded separation from all the selenium-containing coproducts, 
compound 3 was obtained in 89% yield. 
 
Scheme 44. Selenoxide elimination method, 3rd step 
The target α,β-unsaturated δ-lactam, which will be used in the subsequent cycloaddition 
reaction, was thus obtained in overall (3 steps) 45% yield. 
 
3.1.2. Synthesis of the hydrazonoyl chloride, precursor of the 1,3-
dipole 
Afterwards, we moved to the synthesis of the precursor of the nitril-imine, ethyl-3-(2-(1-
chloro-2-methoxy-2-oxoethyiliden)hydrazinylbenzoate 4. A well-established method for 
the obtainment of C-carboxyalkyl-N-aryl hydrazonoyl chlorides is the Japp-Klingermann 
reaction, involving the nucleophilic attack of the enolate of a 2-chloro-1,3-keto-ester on 
an aryl diazonium salt, followed by deacylative elimination. So, reaction of ethyl 3-
aminobenzoate with NaNO2 and concentrated HCl in cold MeOH formed the diazonium 
salt that was subsequently reacted with methyl 2-chloro-acetoacetate with a large excess 
of sodium acetate as the nucleophile for the final elimination. Common aqueous workups 
provided finally product 4 in 92 % yield. This synthesis is very easy to perform on a very 
large scale and leads to a solid and stable product that can be stored for months. 
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Scheme 45 Japp-Klingermann reaction for the synthesis of the hydrazonoyl chloride 
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3.2. 1,3-Dipolar cycloaddition of the nitril-imine with the α,β-
unsaturated δ-lactam followed by oxidation: synthesis of the 
ring-fused pyrazolic core 
With the dipolarophile and the precursor of the 1,3-dipole in hand, the best reaction 
conditions for the [3+2] dipolar cycloaddition were then investigated.  
First of all, taking into account the previous work of our research group33,34,40,46 underling 
the requirement of high boiling anhydrous solvents for the reaction to occur, 1,4-dioxane 
and toluene were tested, either at reflux or at 140 °C (sealed tube), and refluxing toluene 
proved to be the best choice.  
Subsequently, a brief base screening was conducted and the reaction was found to be 
quite base sensitive: in fact, only aliphatic tertiary amines (such as Et3N or DIPEA, N,N’-
diisopropylethylamine) were able to promote the conversion of the hydrazonoyl chloride 
into the desired nitrile-imine and perform the addition.  
Finally, since the major by-products arose from the decomposition of the nitrile-imine, a 
reverse in the stoichiometry ratio was attempted, but it resulted in a deterioration of the 
yield. In summary, the best reaction conditions were found to be Et3N as a base, 1.5 
equivalents of the hydrazonoyl chloride in refluxing toluene.  
On the other hand, the subsequent aromatization step was rather trivial: it involved 
suspension of the cycloaddition crude product in a mixture of THF and water and 
treatment with cerium ammonium nitrate (CAN). The desired product 5a was thus 
obtained in an overall (2 steps) 34% yield after purification by column chromatography 
on silica gel, which also afforded easy and complete separation from regioisomer 5b.  
All the modification performed affected the yield but not the regioselectivity of the 
reaction, that was found to be 5:1 in favour of 5a (from the 1HNMR spectrum of the 
crude oxidized product).  
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Table 1. Reaction conditions for the 1,3 dipolar cycloaddition followed by oxidation 
 
Entry  Solvent  Temp. (°C) Base Equiv. of 4  Yield (%)(b)
1  1,4‐Dioxane  100 Et3N 1.5 24 
2  1,4‐Dioxane  140(c) Et3N 1.5 27 
3  Toluene  110 Et3N 1.5 34 
4  Toluene  140(c) Et3N 1.5 decomp.
5  Toluene  110 DIPEA 1.5 27 
6  Toluene  110 Cs2CO3  1.5 decomp.
7  Toluene  110 DBU(d) 1.5 0 
8(e)  Toluene  110 Et3N 0.75 27
(f) 
(a) Reaction conditions: 3 (0.25 mmol), 4 (0.375 mmol), base (2.625 mmol, 7 eq. referred to 4), 
solvent (1.5 mL), 65h; then CAN (0.625 mmol), THF/H2O 8:6 (3.5 mL), 0 °C, 2 h. (b) Yield of 5a 
isolated after column chromatography, referred to 3. (c) Sealed tube. (d) 1,5-diazabiciclo(5.4.0)undec-
5-ene. (e) Reaction conditions: 3 (0.28 mmol), 4 (0.18 mmol), base (1.29 mmol, 7 eq. referred to 4), 
solvent (1.2 mL), 65h; then CAN (0.7 mmol), THF/H2O 8:6 (3 mL), 0 °C, 2 h. (f) Referred to 4. 
Despite the best yield obtained was quite modest, this method still represents, to our 
knowledge, the only straightforward synthetic strategy to a ring-fused pyrazole. We 
should also consider that the final values refer always to a two-step procedure 
cycloaddition plus oxidation. Moreover, it also proved to be better performing, in terms 
of overall yield, compared to other very similar synthetic sequences. 
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In particular, one synthetic route to Apixaban47 shows a much better yielding 
“cycloaddition”-aromatization step, due to an enamine-driven reaction pathway, in which 
the dipolarophile double bond is much more nucleophile and reactive towards the 
electrophilic center of the nitrile-imine. Aromatization is obtained by a subsequent, acid 
catalyzed, morpholine elimination. This also produced a complete regioselectivity, on 
account of a stepwise mechanism. However, the insertion of the morpholine “activator” 
on the lactamic scaffold involves a much more problematic synthesis of the substrate, 
resulting in a diminished overall yield from δ-valerolactam to the desired ring-fused 
pyrazole. 
 
Scheme 46. Comparison between this work and the Apixaban route 
a) PCl5, CHCl3, 66% yield; b) Li2CO3, DMF, 62% yield; c) morpholine, Et3N, 43% yield; d) Et3N, 
toluene then TFA, DCM, 62% yield 
e) n-BuLi, MOMCl, THF, 77% yield; f) LDA, PhSeBr, THF, 65% yield; g) H2O2, THF, 89% yield; h) 
4, Et3N, toluene, 34% yield then CAN, THF/H2O, 34% yield. 
Finally, in order to attribute the exact structure of the desired regioisomer, X-Ray 
diffraction analysis was performed on a single crystal of product 5a. The structure shown 
is in complete agreement with the theoretical and experimental studies conducted by our 
research group and reported in the introduction (vide supra). 
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Scheme 47. X-ray structure of the major regioisomer 5a (Black = C; White = H; Red= O;  
Green = N) 
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3.3. Synthesis of the “side chain” 
The synthesis of the side chain consisted in a very efficient optimized 4 steps method, 
starting from commercially available inexpensive starting materials and easily applicable 
on a multigram laboratory scale. 
In the first step nucleophilic aromatic substitution of N-Boc-4-hydroxypiperidine (7) on 
1-fluoro-4-nitrobenzene was performed in dry N,N’-dimethylacetamide (DMA), using 
NaH as a base. After purification by column chromatography on silica gel, product 8 was 
obtained in 89% yield. 
 
Scheme 48. Side chain synthesis, 1st step: nucleophilic aromatic substitution 
Reduction of the nitro group of 8 into amine 9 was achieved by catalytic hydrogenation 
using HCOONH4 (ammonium formate) as hydrogen source, 10% Pd on activated carbon 
as catalyst and degassed MeOH as solvent. Product 9 was thus obtained in 95% yield 
without any further purification. 
 
Scheme 49. Side chain synthesis, 2nd step: reduction 
The third step of this strategy involves the attack of the amino group of 9 on the aromatic 
ring of 4-bromo-1-nitrobenzene for the formation of the desired nitroamine (10). 
However, arylamines synthesis with the formation of a new C-N bond is quite difficult, 
since classic nucleophilic aromatic substitution requires very often too harsh reaction 
conditions to take place. Buchwald-Hartwig coupling48 was therefore taken into account 
as a feasible synthetic strategy. Despite the use of a microwave or a sealed tube was 
required by the initial procedure to reach a temperature of 140 °C, treatment of 9 and 4-
bromo-1-nitrobenzene with catalytic Pd(OAc)2 (palladium acetate), catalytic BINAP 
(2,2’-bis(diphenylphosphino)-1,1’-binaftalene) as ligand and Cs2CO3 as a base in 
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refluxing toluene for 65 h resulted in a complete and smooth conversion. After 
purification by column chromatography on silica gel, product 10 was thus obtained in 
90% yield.  
 
Scheme 50. Side chain synthesis, 3rd step: Buchwald-Hartwig coupling 
In the final step reduction of 10 to 11 (91% yield) was achieved again by treatment with 
ammonium formate with Pd/C in refluxing MeOH without any further purifications. The 
desired “side chain” amine 11 was thus obtained in overall (4 steps) 69% yield. 
 
Scheme 51. Side chain synthesis, 4th step: reduction 
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3.4. Functionalization and deprotection 
Initially, diacid 6 was easily obtained by saponification of diester 5a (treatment with 
excess aqueous NaOH in hot methanol followed by protonation with diluted HCl and 
solvent extraction) in 90% yield.  
 
Scheme 52. Saponification 
Once the diacid core 6 and the amine “side chain” 11 were synthesized on the 
appropriate scale, our final efforts were focused on the coupling reaction to obtain the 
protected diamide 13. Different activation methods were attempted, starting from the 
acid chloride. This desired reactive intermediate was formed easily both with thionyl 
chloride (SOCl2) and oxalyl chloride (C2O2Cl2). However, this activated intermediate 
failed to react with amine 11 in the subsequent acylic nucleophilic substitution reaction, 
leading only to decomposition byproducts. 
Activation with CDI (N,N’-carbonyldiimidazole) was tried next and once again the 
reactive intermediate was formed but, due to its extreme insolubility both in THF and in 
DMF (N,N’-dimethylformamide), did not react with the amine and decomposed upon 
work up. 
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a) SOCl2, neat, 50 °C, 2 h (solv = DCM); b) (COCl)2, cat. DMF, neat, 0°C to RT, 2 h (solv. = DCM); 
c) CDI (1.5 eq), THF or DMF, RT, 2 h (R = , solv = THF or DMF) 
Scheme 53. Failed activation methods 
Finally, activation with DCC (N,N’-dicyclohexylcarbodiimide) and NHS (N-hydroxy 
sucinimide) in anhydrous THF worked well but reaction of 6a with 2.2 equivalents of 11, 
at room temperature, gave unexpectedly intermediate 12 as single product, which proved 
to be surprisingly stable towards aqueous work up and purification by column 
chromatography on silica gel (after which it was isolated in 45% yield and completely 
characterized). 
While further treatment of purified 12 with 2 additional equivalents of 11 at 50 °C in 
THF for 65 h gave product 13 in 52% yield after purification by column chromatography 
on silica gel, any attempt to synthesize 13 directly from 6 was completely unsuccessful. 
On account of the enhanced stability of the NHS-ester group of 12, both an activation 
with a catalytic amount (10 mol%) of NHS and a direct treatment of the double-activated 
intermediate 6a with 5 equivalents of 11, either at 50 °C or at RT, were attempted, but 
failed to give any trace of the desired product. For these reasons isolation of intermediate 
12 seemed to be necessary for the process to be successful. 
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Scheme 54. Diamide formation 
This additional purification step is undoubtedly a drawback in the process aiming for the 
double substituted amide product. However, the unexpected stability of the activated 
intermediate 12 discloses a very interesting path for further functionalization of the 
central scaffold with different “side chains”, leading to unsymmetrically substituted 
amidic compounds. This could be a very convenient path to vary the affinity of the core 
for specific biological receptors and will be investigated by the research group in the next 
future.  
In order to exploit this pathway, the structure of compound 12 must be exactly known. 
From 1HNMR analysis it resulted that it exists in a regioisomerically pure form but, at 
present time, we are not completely sure about which of the two activated carboxylic 
acids of 6a reacted with 11. From preliminary 1HNMR studies it is quite probable that 
structure 12 is correct but bidimensional NMR studies, along with attempts to obtain a 
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single crystal for X-rays diffraction, are ongoing in our research group, in order to 
confirm this initial hypothesis. 
As the last step of the synthetic sequence, deprotection of the three protecting groups was 
achieved in a single reaction, by treatment of 13 with HCl 3M in EtOAc. This had been 
possible due to the initial introduction of MOM and Boc groups, both cleavable under 
acidic conditions. Purification by trituration in MeOH and subsequent semi-preparative 
HPLC furnished a high purity sample of 14, suitable for in vitro biological tests. 
 
Scheme 55. Deprotection and purification: obtainment of the final molecular target 
3.5. Biological test 
Molecule 14*2TFA (from preparative HPLC) has been sent to the Biology Laboratory of 
Doctor Mario Chiariello, Istituto Toscano Tumori, Siena. This collaborating group 
performed a first test of cell viability in vitro on uterine cervical cancer cells (namely, 
HeLa cells). As one can see in Scheme 56, this showed a very good result of IC50 with a 
concentration of 1.3 μM after 48 hours of incubation and of 1.85 μM after 24 hours, 
which is comparable with the most common anticancer drugs.12 
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Scheme 56. Plot of the cell viability test. Continue curves represent the trend of the viability or 
cytotoxicity of HeLa cells treated with different concentrations of 14*2TFA. Dotted vertical lines 
represent the value of IC50 after 24 or 48 hours of incubation. 
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4. Conclusions 
In conclusion, a double functionalized bicyclic lactam-fused pyrazole system, with 
promising anticancer activity, has been obtained through a highly convergent synthetic 
strategy. Every step has been optimized in terms of yield, selectivity and feasibility and 
every intermediate has been fully characterized, in order to ensure a practical and 
reproducible pathway from inexpensive starting materials to a highly functionalized 
molecular target.  
More in detail, a wide spectrum of synthetic strategies towards the dipolarophile (α,β-
unsaturated δ-lactam 3) has been investigated and the “selenoxide elimination” has been 
chosen as the best alternative to obtain the desired product in high yields and on a quite 
large laboratory scale.  
Since the synthesis of the hydrazonoyl chloride 4 and the “side chain” 11 were already 
established on a small scale, we focused on laboratory scale-up and optimization. These 
features were completely achieved and very efficient synthetic pathways were found and 
adopted to obtain suitable amounts of high-purity key intermediates. 
The construction of the central bicyclic core has been our main issue. A straightforward 
procedure, namely 1,3-dipolar cycloaddition followed by oxidative aromatization, 
established by our research group, has been employed. Screening of reaction conditions 
and characterization studies about the regioselectivity have been successfully performed. 
Subsequently, functionalization via amide-bond formation was achieved through a two-
steps procedure which serendipitously disclosed a very convenient synthetic pathway to 
construct a library of compounds on the same central core. This particular feature, along 
with a deepest characterization of key intermediate 12 will be developed by our research 
group in the next future. 
On the other end, a high purity sample of target compound 14 has been obtained. This 
showed a good result of IC50 towards one type of cancer cells in a first test in vitro 
performed by a collaborating biology group. More biological tests and chemical 
characterizations are ongoing now in our research groups. 
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5. Experimental section 
General Methods. 1H, 13C NMR spectra were recorded on a Varian AS 300, 400 or 600 
spectrometer. Chemical shifts (δ) are reported in ppm relative to residual solvent signals 
for 1H and 13C NMR. Multiplicity is explained in brackets as follow: “s”, singlet; “d”, 
doublet; “t”, triplet; “q”, quadruplet; “sept”, septuplet; “m”, multiplet; a “b” before the 
letter means “broad” 13C NMR spectra were acquired with 1H broad band decoupled 
mode. Chromatographic purifications were performed using 70-230 mesh silica. Mass 
spectra were recorded on a micromass LCT spectrometer using electrospray (ES) 
ionisation techniques or using electron impact (EI) ionisation techniques. IR spectra were 
recorded on a Perkin-Elmer 177 in CCl4 and on a FT-IR Perkin-Elmer 1600 in KBr. 
Fusion points were measured on a Buchi SMP-20 apparatus and are uncorrected. 
 
Materials. Analytical grade solvents and commercially available reagents were used as 
received. Anhydrous THF was obtained by standing overnight on KOH, filtration 
through a short pad of basic alumina and distilled over Na/benzophenone. All the 
reactions demanding anhydrous conditions were performed in nitrogen atmosphere, 
passed through CaCl2 and silica gel with indicator. Anhydrous toluene was obtained by 
distillation on Na. Dry DMF was obtained by overnight standing on activated 4 Å 
molecular sieves. Degassed MeOH was obtained by bubbling a nitrogen flux in an ice 
bath. 
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Synthesis of 1-(methoxymethyl)piperidin-2-one (1) 
In an oven dried round bottom flask equipped with a magnetic stirring 
bar and under nitrogen atmosphere, 2-piperidinone (5.00 g, 50.4 mmol) 
was dissolved in 50 mL of anhydrous tetrahydrofuran (THF) and the 
solution was cooled to -50°C. Then n-butyllithium 1.6 M in hexanes 
(36 mL, 57.6 mmol) was added dropwise, the resulting mixture was placed in an ice bath 
and allowed to warm up to 0 °C. After 30 min, 4.2 mL of chloromethyl methyl ether 
(MOM-Cl, 55 mmol) were slowly added and the reaction was stirred at room temperature 
for 3h.  
Hereafter, the reaction was quenched with water (20 mL), diluted with hexane and 
washed with water (50 mL) and brine (50 mL). The aqueous phases were extracted with 
dichloromethane (DCM, 3x50 mL), the combined organic extracts were washed again 
with brine (50 mL), dried over MgSO4 and concentrated in vacuo. The crude yellow oil 
was purified either by column chromatography on silica gel (Ethyl Acetate 
(EtOAc)/Hexane (Hex) 2:1) or by vacuum distillation (3 mbar, 130 °C, oil bath 
temperature) to afford 5.50 g (38.5 mmol; 77% yield) of 1-methoxymethyl-piperidin-2-
one 1 as a colourless oil. 
 
1HNMR (300 MHz, CDCl3) δ = 4.79 (s, 2H); 3.35-3.32 (m, 2H); 3.28 (s, 3H); 2.42-2.39 
(m, 2H); 1.82-1.77 (m, 4H) ppm. 13CNMR (100 MHz, CDCl3) δ = 171.4; 77.3; 56.2; 
46.5; 32.7; 23.3; 21.5 ppm. GCMS (EI) m/z = 143 [M+], 128 [M - Me]+. 
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Synthesis of 1-(methoxymethyl)-3-(phenylselenyl)piperidin-2-one (2) 
In an oven dried round bottom flask equipped with a 
magnetic stirring bar and under nitrogen atmosphere, 
diisopropylamine (2.97 mL, 21.2 mmol) was dissolved in 21 
mL of anhydrous THF and the solution was cooled to     -
78°C. Then, n-butyllithium 1.6 M in hexanes (13.2 mL, 21.2 mmol) was added dropwise 
over a period of 20 min and the resulting mixture was stirred for additional 30 min. A 
solution of product 1 (2.76 g, 19.3 mmol) in anhydrous THF (14 mL) was then added 
dropwise and the reaction mixture was left stirring for 1.5 h at -78 °C. In another oven 
dried round bottom flask equipped with a magnetic stirring bar and under nitrogen 
atmosphere, the previously formed reaction mixture was added via syringe, in portions, 
to a solution of phenylselenyl bromide (5.00 g, 21.9 mmol) in anhydrous THF (20 mL) 
cooled to -78 °C. The resulting yellow suspension was stirred at -78 °C for 18 h. 
Hereafter, the reaction was quenched with water (45 mL) and the THF was removed in 
vacuo. The mixture was extracted with DCM (3x50 mL), the organic extracts were 
washed with brine (50 mL), dried over MgSO4 and concentrated in vacuo. The crude red 
oil was purified by column chromatography on silica gel (Hex/EtOAc 1:1) to afford 3.76 
g (12.6 mmol, 65% yield) of 2 as an orange oil. 
 
1HNMR (300 MHz, CDCl3) δ = 7.70-7.67 (m, 2H), 7.33-7.27 (m, 3H); 4.86-4.78 (m, 
2H); 4.04 (t, J = 5.3 Hz, 1H); 3.41-3.35 (m, 2H); 3.30 (s, 3H); 2.22-2.00 (m, 3H); 1.87-
1.75 (m, 1H) ppm. 13CNMR (100 MHz, CDCl3) δ = 169.5; 134.2; 128.1; 127.2; 76.4; 
55.1; 44.8; 41.8; 27.9; 19.9 ppm. GCMS (EI) m/z = 295 [M (76Se)] +, 296 [M (77Se)]+, 
297 [M (78Se)]+, 299 [M (80Se)]+, 301 [M (82Se)]+, 142 [M - SePh]+. 
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Synthesis of 1-(methoxymethyl)-5,6-dihydropyridin-2(1H)-one (3) 
In a round bottom flask equipped with a magnetic stirring bar, product 
2 (2.75 g, 9.22 mmol) was dissolved in THF (27.5 mL) and cooled to 0 
°C. Then, a solution of H2O2 35% w/w in H2O (1.79 g, 18.44 mmol) 
was slowly added and the reaction mixture was stirred for 30 min. The 
ice bath was removed, the temperature was allowed to rise slowly up to 25 °C (Caution: 
highly exothermic reaction!) and the reaction was stirred for 2 h. 
Hereafter, water (20 mL) was added and the THF was removed in vacuo, The mixture 
was extracted with DCM (2x50 mL), the organic extracts were washed with a half 
saturated solution of NaHCO3 (3x50 mL) and brine (50 mL), dried over MgSO4 and 
evaporated in vacuo. The crude orange oil was purified by column chromatography on 
silica gel (DCM, then DCM/MeOH 20:1) to afford 1.16 g (8.19 mmol, 89% yield) of 3 as 
a pale brown oil. 
 
1HNMR (300 MHz, CDCl3) δ = 6.63 (dt, J1 = 9.9 Hz, J2 = 4.30 Hz, 1H); 5.96 dt (J1 = 9.8 
Hz, J2 = 1.87 Hz, 1H); 4.84 (s, 2H); 3.48 (t, J = 7.08 Hz, 2H), 3.31 (s, 3H), 2.44-2.38 (m, 
2H) ppm. 13CNMR (100 MHz, CDCl3) δ = 165.1; 140.9; 125.1; 76.8; 55.9; 43.6; 24.2 
ppm. IR (CCl4) ν = 2949.0, 2870.3, 1724.6, 1659.8 cm
-1. ESIMS 164 [M + Na+] 
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Synthesis of ethyl 3-(2-(1-chloro-2-methoxy-2-oxoethylidene)hydrazinyl)benzoate 
(4) 
In a round bottom flask equipped with a magnetic stirring bar, 
ethyl 3-aminobenzoate (8.00 g, 48.4 mmol) was dissolved in 
methanol (MeOH, 50 mL), the solution was cooled to -20 °C and 
HCl 6N (100 mL, 600 mmol) was carefully added. Then NaNO2 
(6.68 g, 96.8 mmol) was added slowly in portions; the resulting 
mixture was stirred at 0 °C for 15 min and sodium acetate was 
added until pH = 5 was reached. Finally, a solution of 2-chloro-
acetoacetate (7.28 g, 48.4 mmol) in 60 mL of MeOH was added dropwise through a 
dropping funnel; the ice bath was removed and the dense orange suspension was stirred 
at room temperature for 18 h. 
After removal of all the MeOH in vacuo, the mixture was diluted with diethyl ether 
(Et2O, 200 mL), washed with a saturated solution of NaHCO3 (5x100 mL) until gas 
evolution was no longer observed, washed again with brine (2x75 mL), dried over 
MgSO4 and evaporated in vacuo to give 12.55 g (44.12 mmol, 91% yield) of pure 4  as 
an orange solid (f. p. = 108-110 °C). 
 
1HNMR (400 MHz, CDCl3) δ = 8.40 (bs, 1H); 7.80 (m, 1H); 7.75-7.73 (m, 1H); 7.50-
7.45 (m, 1H); 7.41-7.39 (m, 1H); 4.38 (q, J = 7.0 Hz, 2H); 3.95 (s, 3H); 1.40 (t, J = 7.2 
Hz, 3H) ppm. 13CNMR (75 MHz, CDCl3) δ = 165.1; 160.1; 141.8; 131.8; 129.6; 124.1; 
118.7; 116.5; 115.4; 61.2; 53.6; 14.3 ppm. IR (KBr) ν = 3273.4, 2988.4, 1732.9, 1717.0, 
1557.6, 1076.1 cm-1. ESIMS 307 [M (35Cl) + Na+], 309 [M (37Cl) + Na+]  
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Synthesis of methyl 1-(3-(ethoxycarbonyl)phenyl)-6-(methoxymethyl)-7-oxo-4,5,6,7-
tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate (5a) 
In an oven dried round bottom flask equipped with a 
magnetic stirring bar and under nitrogen atmosphere, 
product 3 (1.41 g, 10.0 mmol) and product 4 (4.27 g, 15.0 
mmol) were stirred in toluene (60 mL) until a clear 
solution was obtained. Triethylamine (14.62 mL, 105 
mmol) was then added and the reaction was refluxed at 
110 °C for 65 h.  
The reaction mixture was cooled to room temperature, filtered through a short plug of 
celite and evaporated in vacuo. The crude product was directly suspended in 140 mL of 
an 8:6 THF/water mixture and cooled to 0 °C. Cerium ammonium nitrate (CAN, 13.7 g, 
25.0 mmol) was then added in portions and the reaction mixture was stirred at 0 °C for 2 
h. 
After removal of all the THF in vacuo, the mixture was extracted with EtOAc (3x75 
mL), the organic extracts were washed with brine (75 mL), dried over MgSO4 and 
evaporated in vacuo. The crude red sticky oil was purified by column chromatography on 
silica gel (Hex/EtOAc 1:1) to afford 1.32 g (3.4 mmol, 34% yield) of 5a as a yellow solid 
(f. p. = 113-114 °C). 
 
1HNMR (300 MHz, CDCl3) δ = 8.21 (m, 1H); 8.12 (m, 1H); 7.77-7.73 (m, 1H); 7.53 (t, J 
= 7.8 Hz, 1H); 4.29 (s, 2H); 4.37 (q, J = 7.2 Hz, 2H); 3.97 (s, 3H); 3.77 (t, J = 6.9 Hz, 
2H); 3.32 (s, 3H); 3.22 (t, J = 6.9 Hz, 2H); 1.38 (t, J = 7.1, 3H) ppm. 13CNMR (100 
MHz, CDCl3) δ = 165.4; 162.2; 157.8; 139.5; 139.3; 132.8; 131.2; 130.1; 129.8; 128.6; 
127.6; 126.8; 76.5; 61.3; 56.2, 52.2; 46.0; 21.0; 14.3 ppm. IR (KBr) ν = 2961.0, 1713.2, 
1671.6, 1591.7, 1253.8, 1089.5 cm-1. ESIMS 410 [M + Na+] 
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Synthesis of 1-(3-carboxyphenyl)-6-(methoxymethyl)-7-oxo-4,5,6,7-tetrahydro-1H-
pyrazolo[3,4-c]pyridine-3-carboxylic acid (6) 
In round bottom flask equipped with a magnetic stirring bar, 
product 5a (1.32 g, 3.4 mmol) was dissolved in MeOH (20 
mL) and heated to 50 °C, then a solution of NaOH (0.54 g, 
13.6 mmol) in 7 mL of water was added dropwise and the 
reaction was stirred for 3h.  
Hereafter, water (10 mL) was added, the MeOH was 
removed in vacuo and the aqueous phase was washed with DCM (3x30 mL), acidified 
with HCl 1 N until pH = 1 was reached and extracted with EtOAc (3x30 mL). The 
combined organic extracts were dried over MgSO4 and evaporated in vacuo to give 1.06 
g of product 6 (3.06 mmol, 90% yield) as a red solid (f. p. = 200 °C with decomposition) 
 
1HNMR (400 MHz, CD3OD) δ = 8.20 (m, 1H); 8.10 (m, 1H); 7.80 (m, 1H); 7.57 (m, 
1H); 4.80 (s, 2H); 3.70 (t, J = 6.7 Hz, 2H); 3.25 (s, 3H); 3.10 (t, J = 6.9 Hz, 2H) ppm. 
13CNMR (100 MHz, CD3OD) δ = 171.1; 167.1; 162.1; 144.0; 143.4, 136.6, 135.2; 133.6, 
133.4; 132.4, 132.0, 130.3, 80.3; 50.0; 24.6 ppm. IR (KBr) ν = 3011.8 1712.3, 1672.7, 
1591.6, 1223.1, 760.1 cm-1. ESIMS 368 [M + Na+] 
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Synthesis of tert-butyl 4-(4-nitrophenoxy)piperidine-1-carboxylate (8) 
In an oven dried round bottom flask equipped with a 
magnetic stirring bar and under nitrogen atmosphere, 
NaH 60% in mineral oil (1.76 g, 44.0 mmol) was washed 
with hexane (3x20 mL) and dried at the high vacuum 
pump. The flask was filled again with nitrogen and placed in an ice bath; dry N,N’-
dimethylacetamide (DMA, 130 mL) and 7 (N-Boc-4-hydroxypiperidine, 8.16 g, 40 
mmol) were added in this order and stirred vigorously for 15 min. A solution of 1-fluoro-
4-nitrobenzene (5.5 mL, 52.24 mmol) in 20 mL of dry DMA was then added in one 
portion (a moderate but prolonged heat evolution was observed) and the reaction mixture 
was stirred at room temperature for 4 h. 
Hereafter, the reaction was quenched with a saturated solution of NH4Cl (100 mL) and 
diluted with EtOAc (200 mL); the phases were separated and the organic extract was 
washed with brine (3x100 mL), dried over MgSO4 and evaporated in vacuo. The crude 
brown oil was purified by column chromatography on silica gel (Hex/EtOAc 5:1) to give 
11.42 g (35.4 mmol, 89% yield) of 8 as a bright yellow powder (f. p. = 100-102 °C). 
 
1HNMR (400 MHz, CDCl3) δ = 8.21-8.17 (m, 2H); 6.97-6.93 (m, 2H); 4.60 (sept, J = 3.5 
Hz, 1H); 3.72-3.66 (m, 2H); 3.41-3.34 (m, 2H); 1.99-1.92 (m, 2H); 1.82-1.74 (m, 2H); 
1.47 (s, 9H) ppm. 13CNMR (100 MHz, CDCl3) δ = 162.8; 155.1; 141.8; 126.4, 115.7, 
80.2, 73.3; 40.8 (broad); 30.6; 28.8 ppm. IR (KBr) ν = 2954.2, 1698.2, 1590.8, 1509.3, 
1412.9, 1340.5, 1262.3 cm-1. GCMS (EI) m/z = 322 [M+], 266 [M - isobutylene]+, 249 
[M - iBuO]+, 222 [M – isobutylene - CO2], 184 [M – PhNO2, - H2O]
+, 128 [M - PhNO2, - 
H2O – isobutylene]
+, 84 [M - PhNO2, - H2O - isobutylene - CO2]
+. 
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Synthesis of tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate (9) 
In a round bottom flask equipped with a magnetic stirring 
bar and under nitrogen atmosphere, product 8 (11.42 g, 
35.4 mmol) and ammonium formate (21.52 g, 354 mmol) 
were dissolved in 210 mL of degassed MeOH and the 
solution was heated to 50 °C. 10% w/w Palladium on activated charcoal (1.10 g) was 
added and the reaction mixture was stirred at 90 °C for 5 h. 
Hereafter, the reaction mixture was filtered through a short plug of celite, washed with 
DCM (100 mL) and evaporated in vacuo to give 9.28 g (32.2 mmol, 95% yield) of pure 9 
as a brown solid (f. p. = 80-81 °C). 
 
1HNMR (300 MHz, CDCl3) δ = 6.77-6.71 (m, 2H); 6.63-6.58 (m, 2H); 4.24 (sept, J = 3.6 
Hz, 1H); 3.73-3.65 (m, 2H); 3.46 (bs, 2H); 3.29-3.21 (m, 2H); 1.90-1.81 (m, 2H); 1.73-
1.62 (m, 2H); 1.45 (s, 9H) ppm. 13CNMR (100 MHz, CDCl3) δ = 154.9; 150.0; 140.7, 
118.3; 116.4; 79.5; 73.7; 40.7 (broad); 30.8; 28.4 ppm. IR (KBr) ν = 3460.0, 3361.6, 
2955.4, 1685.1, 1509.9, 1419.4, 1229.0, 1049.6 cm-1. GCMS (EI) m/z = 291 [M+], 219 
[M - iBuO]+, 192 [M – isobutylene - CO2], 184 [M – PhNH2, - H2O]
+, 128 [M - PhNH2, - 
H2O - isobutylene]
+, 109 [4-aminophenol]+, 84 [M - PhNH2, - H2O - isobutylene - CO2]
+. 
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Synthesis of tert-butyl 4-(4-((4-nitrophenyl)amino)phenoxy)piperidine-1-carboxylate 
(10) 
In an oven dried round bottom flask equipped 
with a magnetic stirring bar and under nitrogen 
atmosphere, product 9 (9.22 g, 32 mmol), 1-
bromo-4-nitrobenzene (6.45 g, 32 mmol), 
palladium acetate (1.10 g, 4.8 mmol), 2,2′-Bis(diphenylphosphino)-1,1′-binaphthalene 
(BINAP, 3.00 g, 4.8 mmol) and Cs2CO3 (13.9 g, 42.7 mmol) were suspended in 
anhydrous toluene (270 mL) and the resulting mixture was refluxed for 65 h. 
Hereafter, the reaction mixture was filtered through a short plug of celite, washed with 
DCM (150 mL) and evaporated in vacuo. The crude brown solid was purified by column 
chromatography on silica gel (Hex/EtOAc 2:1) to afford 11.93 g (28.9 mmol, 90% yield) 
of 10 as an intense orange solid (f. p. = 150-152 °C). 
 
1HNMR (400 MHz, CDCl3) δ = 8.10-8.06 (m, 2H); 7.16-7.12 (m, 2H); 6.95-6.91 (m, 
2H); 6.80-6.76 (m, 2H); 6.26 (bs, 1H); 4.45 (sept, J = 3.7 Hz, 1H); 3.74-3.68 (m, 2H); 
3.37-3.31 (m, 2H); 1.97-1.89 (m, 2H); 1.80-1.72 (m, 2H); 1.47 (s, 9H) ppm. 13CNMR 
(100 MHz, CDCl3) δ = 155.23; 155.19; 151.9; 139.5; 132.8; 126.6; 125.6; 117.6; 113.1; 
80.0; 73.1; 40.9 (broad); 30.8; 28.8 ppm. IR (KBr) ν = 3317.3, 2936.1, 1669.1, 1597.5, 
1508.2, 1323.1, 1242.4 cm-1. ESIMS 436 [M + Na+]. 
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Synthesis of tert-butyl 4-(4-((4-aminophenyl)amino)phenoxy)piperidine-1-
carboxylate (11) 
In a round bottom flask equipped with a magnetic 
stirring bar and under nitrogen atmosphere, 
product 10 (2.57 g, 6.0 mmol) and ammonium 
formate (3.43 g, 54.5 mmol) were dissolved in 60 
mL of degassed MeOH and the solution was heated to 50 °C. 10% w/w Palladium on 
activated charcoal (0.23 g) was added and the reaction mixture was stirred at 90 °C for 5 
h. 
Hereafter, the reaction mixture was filtered through a short plug of celite, washed with 
DCM (40mL) and evaporated in vacuo. The crude product was suspended in DCM (50 
mL), filtered again on celite and washed with DCM (50 mL) to give 2.10 g (5.5 mmol, 
91% yield) of pure 11 as a brown-violet solid (f. p. = 144-145 °C). 
 
1HNMR (300 MHz, CDCl3) δ = 6.89-6.77 (m, 6H); 6.66-6.61 (m, 2H); 4.30 (sept, J = 4.0 
Hz); 3.89 (bs, 3H); 3.75-3.67 (m, 2H); 3.32-3.-24 (m, 2H); 1.93-1.84 (m, 2H); 1.76-1.65 
(m, 2H); 1.47 (s, 9H) ppm. 13CNMR (75 MHz, CDCl3) δ = 154.9; 150.6; 141.3; 139.9; 
135.4; 121.4; 117.9; 117.8; 116.3; 79.5; 73.4; 40.8 (broad); 30.7; 28.5 ppm. IR (KBr) ν = 
3462.2, 3367.5, 2960.0, 1684.8, 1 1506.4, 1424.3, 1228.9, 1057.3 cm-1. ESIMS 406 [M 
+ Na+]. 
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Synthesis of Intermediate 12 
In an oven dried Schlenk flask 
equipped with a magnetic stirring bar 
and under nitrogen atmosphere, diacid 
6 (0.173 g, 0.5 mmol) and N-
hydroxysuccinimide (NHS, 0.173 g, 
1.5 mmol) were dissolved in 
anhydrous THF (7.5 mL). The flask 
was placed in an ice bath, N,N’-dicyclohexylcarbodiimide (0.309 g, 1.5 mmol) was 
added slowly in portions and the reaction mixture was left stirring for 2 h at room 
temperature (a white precipitate was readily formed). A solution of amine 11 (0.460 g, 
1.2 mmol) in anhydrous THF (3.5 mL) was then added dropwise at 0°C and the resulting 
mixture was left stirring for 18 h at room temperature.  
Hereafter, the reaction mixture was filtered through a short pad of celite, diluted with 
EtOAc (30 mL) and washed rapidly with water (4x20 mL) and brine (20 mL). The 
organic phase was dried over MgSO4 and evaporated in vacuo. The crude dark solid was 
purified by column chromatography on silica gel (EtOAc/Hex 5:2) to afford 0.181 g 
(0.224 mmol, 45% yield) of intermediate 12 as a dark yellow solid (f. p. = 127-130 °C). 
 
1HNMR (600 MHz, CDCl3) δ = 8.65 (bs, 1H); 8.35 (m, 1H); 8.20 (m, 1H); 7.95-7.91 (m, 
1H); 7.66 (t, J = 8.2, 1H); 7.56-7.54 (m, 2H); 7.04-7.01 (m, 2H); 6.96-6.94 (m, 2H); 6.88-
6.85 (m, 2H); 5.50 (bs, 1H); 4.91 (s, 2H); 4.37 (m, 1H); 3.79 (t, J = 7.1 Hz, 2H); 3.74-
3.70 (m, 2H); 3.35-3.29 (m, 4H overlapped with s, 3H); 2.92 (bs, 4H); 1.93-1.89 (m, 2H); 
1.77-1.71 (m, 2H); 1.47 (s, 9H) ppm. 13CNMR (75 MHz, CDCl3) δ = 168.0; 160.0; 
158.0; 156.9; 153.9; 151.3; 141.5; 140.5; 138.7; 135.7; 132.3; 130.9; 129.7; 128.9; 128.1; 
126.3; 125.8; 124.9; 120.6; 120.0; 116.6; 115.8; 78.6; 76.2; 72.1; 55.2; 45.2; 39.6 
(broad); 29.6; 27.4; 24.7; 19.8 ppm. IR (KBr) ν = 3497.0, 3350.9, 2929.0, 1773.4, 
1741.0, 1674.3, 1595.4, 1504.3, 1423.4, 1229.2 cm-1. ESIMS 830 [M + Na+]. 
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Synthesis of protected diamide 13 
In an oven dried Schlenk flask 
equipped with a magnetic stirring 
bar and under nitrogen 
atmosphere, intermediate 12 
(0.140 g, 0.173 mmol) and amine 
11 were dissolved in anhydrous 
THF (1.2 mL) and the resulting 
solution was stirred at 50 °C for 65 h.  
Hereafter, the reaction mixture was diluted with EtOAc (15 mL), washed with water 
(2x15 mL) and brine (15 mL), dried over MgSO4 and evaporated in vacuo. The crude 
product was purified by column chromatography on silica gel (EtOAc/Hex 5:2) to afford 
0.095 g (0.09 mmol, 52% yield) of diamide 13 as a dark green solid (f. p. = 200 °C with 
decomposition). 
 
1HNMR (400 MHz, CDCl3) δ = 8.64 (bs, 1H); 8.13 (m, 1H); 8.05 (bs, 1H); 7.91 (m, 
1H); 7.76-7.74 (m, 1H); 7.56 (t, J = 7.9 Hz, 1H); 7.53-7.47 (m, 4H); 7.04-7.00 (m, 4H); 
6.95-6.91 (m, 4H); 6.88-6.84 (m, 4H); 5.52 (bs, 2H); 4.90 (s, 2H); 4.37 (m, 2H); 3.78-
3.69 (m, 6H); 3.34-3.28 (m, 6H overlapped with s, 3H); 1.94-1.87 (m, 4H); 1.78-1.70 (m, 
4H); 1.47 (s, 18 H) ppm. 13CNMR (100 MHz, CDCl3) δ = 163.4; 158.1; 157.1; 153.9; 
151.3; 141.1; 140.7; 140.6; 138.2; 135.6; 134.8; 132.0; 129.4; 128.8; 127.8; 126.9; 125.9; 
123.1; 121.0; 120.6; 120.04; 120.02; 116.6; 115.8; 115.7; 78.6; 76.2; 72.1;55.2; 45.3; 
39.7 (broad); 29.6; 27.4; 19.9 ppm. IR (KBr) ν = 3493.5, 3360.2, 2929.8, 1773.6, 1749.3, 
1672.9, 1598.3, 1423.5, 1229.2 cm-1. ESIMS 1098 [M + Na+]. 
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Synthesis of final target 14 
In a small vial, 1 mL of HCl (12 M) and 
3 mL of EtOAc were vigorously shacked 
until a homogeneous phase is obtained. 
In a test tube equipped with a magnetic 
stirring bar compound 13 (0.080 g, 0.075 
mmol) was vigorously stirred in 1.5 mL 
of the previously prepared solution for 3 
h at 50 °C (complete dissolution and subsequent precipitation were observed). 
Hereafter, the reaction mixture is evaporated in vacuo to obtain a crude green solid that 
can be purified by trituration in MeOH (3 mL), affording 0.031 g (0.034 mmol, 46% 
yield) of 14*2HCl as a green solid. A high purity sample may be obtained by purification 
with semi-preparative HPLC (stationary phase: C18 “hydro”; eluent: 65% H2O with 
0.01% TFA/35% azeotropic CH3CN), giving 14*2TFA after evaporation of the solvent. 
 
1HNMR (600 MHz, DMSO, d6) δ = 10.18 (s, 1H); 10.04 (s, 1H); 8.44 (bs, 4H); 8.21 (s, 
1H); 8.03 (m, 2H); 7.96-7.81 (m, 3H); 7.66 (s, 1H); 7.60 (m, 4H); 7.09-6.74 (m, 12H); 
4.49 (bm, 2H); 3.50 (bm, 2H); 3.25 (bm, 4H); 3.07 (bm, 6H); 2.05 (bm, 4H); 1.80 (bm, 
4H) ppm. ESIMS 417 [M of 14 + 2]2+ 
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